Navigation Links
ClinStar to Present on Clinical Trial Recruitment in the Emerging Regions of Russia and Eastern Europe
Date:10/18/2011

SAN FRANCISCO, Oct. 18, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov and Manager of Clinical Operations Alexander Kutermin will speak at Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference, November 3-4, in Philadelphia, PA.  

(Logo:  http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

According to the International Agency for Research on Cancer's (a division of the World Health Organization) GLOBOCAN 2008 report, an estimated 12.7 million people worldwide are diagnosed with some form of cancer annually and this number is expected to jump to 21 million by 2030. The emerging markets of Russia, Ukraine, Belarus and the Baltics offer access to a population of more than five million cancer sufferers. By conducting clinical trials in these regions, biopharmaceutical companies can significantly speed enrollment, and thereby, reduce the overall time and cost to develop an oncology drug.  

During the presentation scheduled for Friday, November 4 at 1:30 p.m., Mr. Passov will explore perceptions and comparisons of emerging markets and discuss how to navigate cultural and regulatory challenges in the region in order to optimize recruitment. Mr. Kutermin will present a case study revealing how Russia, Ukraine, Belarus and the Baltics outperformed 20+ other countries in a global, Phase III breast cancer trial.  

Through a series of keynote regional presentations, case studies and interactive panel discussions, Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference will examine the current role that emerging regions play in conducting oncology clinical trials with a focus on the operational, regulatory and logistical challenges involved.  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
2. ClinStar to Present on Conducting Clinical Trials in Russia
3. ClinStar, LLC Establishes New Office on the US East Coast
4. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
5. Renessa® Treatment for Stress Incontinence: Three Year Clinical Results Presented
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
8. PLC Medical Systems CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
10. Ziehm Imaging Presents new 20 kW Ziehm Vision R
11. Amerigroup Foundation Presents Grant to Rx Partnership in Virginia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)... 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Uro/Gyn and Gynecology markets with innovative and proprietary products, ... March 31, 2017 after the market close on Tuesday, ... host a conference call and webcast to discuss its ... 2017 at 4:30 p.m. Eastern Time (3:30 p.m. Central ...
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... It's not always common knowledge whether ... illnesses that are unclear as to whether or not they are contagious, and most ... of these illnesses. So, FindaTopDoc took a look into the matter. , They ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... National Harbor, Md. (PRWEB) , ... April 28, ... ... Urgent Care Association of America (UCAOA) and College of Urgent Care Medicine will ... Momentum 2017 workshops, sessions and speakers will help those in the industry adapt ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
Breaking Medicine News(10 mins):